Jpmorgan Chase & CO Regenxbio Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGNX
# of Institutions
199Shares Held
43.3MCall Options Held
58.9KPut Options Held
58.4K-
Black Rock Inc. New York, NY8.61MShares$75.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$44.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.57MShares$40 Million3.49% of portfolio
-
State Street Corp Boston, MA2.87MShares$25.2 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.3MShares$11.4 Million0.75% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $379M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...